“…All four miRNA gene variant associations noteworthy to detect an OR of 1.1 that were also noteworthy (FPRP < 0.2) were included in these 16 comparisons. The other 12 comparisons were miR‐196a2/rs11614913 T vs. C (OR, 1.21; P < .0001); miR‐27a/rs895819 GG vs. AA + AG (OR, 1.49, P < .001) and colorectal cancer ; miR‐196a2/rs11614913 C vs. T (OR, 1.40, P < .00001) and oesophageal cancer ; miR‐146a/rs2910164 G vs. C (OR, 1.15, P < .001); miR‐196a2/rs11614913 T vs. C (OR, 0.77, P < .00001) and gastric cancer ; miR‐146a/rs2910164 C vs. G (OR, 1.19, P < .001) and bladder cancer ; miR‐499/rs3746444 homozygous model (OR, 1.64, P < .001) and breast cancer ; miR‐146a/rs2910164 CC vs. GG + GC (OR, 0.52, P < .001); miR‐499/rs3746444 (OR, 2.07, P < .001) and cervical cancer ; miR‐499/rs3746444 GA vs. AA (OR, 1.60, P < .001) and prostate cancer ; miR‐146a/rs2910164 CC vs. GG (OR, 1.28, P < .001) and lung cancer ; and miR‐499/rs3746444 G vs. A (OR, 1.57, P < .001) and oral squamous cell cancer …”